

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2004/010430

International filing date: 02 April 2004 (02.04.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/462,407
Filing date: 10 April 2003 (10.04.2003)

Date of receipt at the International Bureau: 07 December 2006 (07.12.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1548778

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 28, 2006

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/462,407

FILING DATE: *April 10, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/10430*

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US60/462,407*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

**UNITED STATES PATENT AND TRADEMARK OFFICE
DOCUMENT CLASSIFICATION BARCODE SHEET**




As-Filed New Application

Level -1
Version 1.1
Updated - 8/01/01

**UNITED STATES PATENT AND TRADEMARK OFFICE
DOCUMENT CLASSIFICATION BARCODE SHEET**



Transmitta



Level - 2
Version 1.1
Updated - 8/01/01

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **EV 010319805 465**

U.S. PTO
462407

INVENTOR(S)

Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)
GU	Hong	St. Louis, Missouri, USA

☐ Additional inventors are being named on the _____ separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

REGIO-SELECTIVE PROCESS A 9-TETRAHYDROCANABINOL FIELD OF THE INVENTION

Direct all correspondence to: **CORRESPONDENCE ADDRESS**

☐ Customer Number _____ **Place Customer Number Bar Code Label here**

OR ☐ Type Customer Number here _____

☐ Firm or Individual Name **Jeffrey S. Boone**

☐ Address **Mallinckrodt Inc.**

☐ Address **675 McDonnell Boulevard, P.O. Box 5840**

☐ City **St. Louis** ☐ State **MO** ☐ ZIP **63134**

☐ Country **USA** ☐ Telephone **314-654-8955** ☐ Fax **314-654-3156**

☒ Specification ☐ Number of Pages **15** ☐ CD(s), Number _____

☐ Drawing(s) ☐ Number of Sheets _____ ☐ Other (specify) _____

☐ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☐ Applicant claims small entity status. See 37 CFR 1.27.

☐ A check or money order is enclosed to cover the filing fees.

☒ The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: **13-1160**

☐ Payment by credit card. Form PTO-2038 is attached.

FILING FEE AMOUNT (\$) **\$160.00**

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted, **Jeffrey S. Boone** Date **2003 APR 9**

SIGNATURE _____

TYPED OR PRINTED NAME **Jeffrey S. Boone**

TELEPHONE **314-654-8955**

REGISTRATION NO. **29,284**

Docket Number: **1560 P US**


USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

UNITED STATES PATENT AND TRADEMARK OFFICE
DOCUMENT CLASSIFICATION BARCODE SHEET



Specification



Level - 2
Version 1.1
Updated - 8/01/01

Case no.1560.P US

REGIO-SELECTIVE PROCESS Δ^9 -TETRAHYDROCANNABINOL FIELD OF THE INVENTION

The present invention relates to the regio-selective synthesis of Δ^9 -hydrodannabinol (THC) and THC derivatives, and more particularly to the condensation reaction of a terpinoid with olivetol and olivetol derivatives using cyclodextrins as space blockers for the regio-selective synthesis of THC.

BACKGROUND OF THE INVENTION

Naturally occurring cannabinoids are the biologically active components of cannabis. Pharmaceutical interest in cannabinoids has increased due to FDA approval of Δ^9 -tetrahydrocannabinol (THC) for several therapeutic applications

In the 1940's A. R. Todd and R. Adams attempted to prepare several synthetic analogs that were shown to have similar activity of marijuana even before the structure of THC was firmly established. Many efforts have been made to develop an efficient strategy to prepare the THC. Among the several approaches to synthesize THC and its derivatives, the condensation of olivetol with several terpene based compounds, such as (-)-verbenol, (+)-chrysanthanol, (+)-p-mentha-2,8-diene-2-ol, (+)-trans-2-carene epoxide, (+)-3-carene oxide and (+)-p-mentha-2-ene-1,8-diol are more efficient than other approaches, such as Diels-Alder reaction of cinnamic acid derivatives, reaction of citral and lithium derivatives of the olivetol and olivetol dimethyl ether and synthetic route to the THC based on the Pechmann condensation reaction. All known synthesis paths share a common drawback-the final product is a resinous, hard to purify, complex mixture

containing up to eight major isomers. As a result, multiple purification steps are often required to purify the THC from the reaction mixture when those synthetic approaches are adopted. Production of THIC and THC derivatives is therefore costly to scale up for commercial purposes.

SUMMARY OF THE INVENTION

An aspect of the present invention is to provide a composition comprising olivetol or an olivetol derivative complexed with at least one cyclodextrin to block unwanted reactions.


Another aspect of the present invention is to provide a process for preparing a cannabinoid compound comprising complexing olivetol or an olivetol derivative with at least one cyclodextrin; and reacting at least one terpene with the complexed olivetol to produce the cannabinoid compound.

These are merely illustrative aspects of the present invention and should not be deemed an all-inclusive listing of the innumerable aspects associated with the present invention. These and other aspects will become apparent to those skilled in the art in light of the following disclosure.

DETAILED DESCRIPTION

A cyclodextrin-olivetol derivative complex is disclosed herein. Cyclodextrins are cyclic oligosaccharides having at least six glucopyranose units. Commercially available cyclodextrins typically have 6, 7 and 8 glucopyranose units. Cyclodextrins are shaped as a torus, with a hydrophilic outer surface and a hydrophobic inner surface. Cyclodextrins are capable of forming inclusion complexes with hydrophobic guest molecules of suitable diameters. These cyclodextrin complexes encapsulate guest molecules.

In the present invention, the cyclodextrin provides its cavity as a non-polar sterically hindered reaction field, in which the olivetol derivative is complexed. In the description below, the term "olivetol derivative" is deemed to include olivetol. The cyclodextrin-olivetol derivative complex is illustrated below.



wherein R_1 and R_2 are H or an alkyl group; and wherein R_3 is an alkyl having 1 to about 10 carbons, branched or unbranched or an aryl (non-polar). When R_1 and R_2 are H and R_3 is a pentyl group, the compound is olivetol.

In the resulting complex, the C_3 and C_5 positions of the olivetol derivative are blocked, thereby preventing unwanted reactions at these carbons. The C_1 carbon is left unprotected and is available for reaction.

Conventional synthesis of cannabinoids from olivetol derivatives requires a condensation reaction of a substrate with the olivetol derivative at C_1 . Reactions at C_3 and C_5 result in unwanted by-products that decrease yield and are difficult to remove.

As a result of the complexation of an olivetol derivative with cyclodextrin, the side reaction pathways related to reactions at the C₃ and C₅ positions have been successfully blocked.

The composition of the cyclodextrin and olivetol derivative non-covalent complex is prepared as an intermediate, which may or may not need to be isolated for further reaction to prepare THC.


The reaction may be carried out in a one or two-step process. For the two-step reaction process, the cyclodextrin-olivetol derivative complex is isolated, and then converted to the desired product at a later time.

The selection of a suitable cyclodextrin depends primarily on the sizing of the non-polar cavity. Cyclodextrins suitable for complexation with olivetol derivatives include but are not limited to natural α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin or modified synthetic cyclodextrin, such as (2-hydroxy-propyl)- β -cyclodextrin, (2-carboxyethyl)- α , β , γ -cyclodextrin, (2,6-Di-O)-ethyl- β -cyclodextrin and (2-hydroxy-ethyl)- β -cyclodextrin.

The cyclodextrin-olivetol derivative complex is formed by mixing the cyclodextrin and olivetol derivative in a suitable solvent. Suitable solvents include but are not limited to tetrahydrofuran, dimethyl-formaldehyde, hydrocarbons, halogenated hydrocarbons, ethers such as diethyl ether, ketones such as acetone and methyl ethyl ketone, alcohols such as methanol, ethanol and isopropyl alcohol and mixtures thereof. Preferred solvents include halogenated hydrocarbons, tetrahydrofuran and dimethyl formaldehyde. The reaction is preferably at room temperature for about 30 minutes,

although time and temperature are not critical. The solvent is then evaporated at reduced pressure, leaving a solid cyclodextrin-olivetol derivative complex.

The reaction of the cyclodextrin-olivetol derivative complex is illustrated below:



To prepare THC cannabinoids, the substrates used in this reaction include (-)-verbenol, (+)-chrysanthanol, (+)-p-mentha-2,8-diene-2-ol, (+)-trans-2-carene epoxide, (+)-3-carene oxide and (+)-p-mentha-2-ene-1,8-diol. These substrates are illustrative and are not meant to be limiting of the present invention.

The preparation of a THC derivative from an olivetol derivative is well known in the art. The process includes dissolving the cyclodextrin-olivetol derivative complex in a solvent system as defined above. While maintaining a reduced temperature, the substrate and an acid catalyst, including but not limited to Lewis acids, are added to the cyclodextrin-olivetol derivative complex. The temperature is typically maintained at

about 0 ° C to about 15 ° C, with about 5 ° C being preferred. The reaction process may be monitored with HPLC, and upon completion of the reaction the reaction may be quenched with a base. The resulting mixture is purified by conventional methods known in the art.

In addition, the above reaction may be altered to result in the formation of a cannabidiol, typically by using a weaker acid catalyst or by reducing the temperature of the reaction, as is well known in the art. The cannabidiol can then be converted to a cannabinoid compound or utilized as an intermediate for a different reaction.

Furthermore, the presence of ABN-cannabidiol has been detected in the reaction mixture, the ABN-cannabidiol being the result of either reaction of the (+)-2,8-menthadiene-1-ol at the C₃ or C₅ position due to incomplete complexation of the cyclodextrin/olivetol, or the result of rearrangement of the normal cannabidiol. In either case, it has been determined the ABN-cannabidiol, in the presence of at least one cyclodextrin and at least one Lewis acid, rearranges to normal cannabidiol.

The following examples are offered to illustrate aspects of the present invention, and are not intended to limit or define the present invention in any manner

EXAMPLES

Example 1

The preparation of 5-pentyl-1,3-benzenediol/cyclodextrin complex:

5 g of olivetol and 31 g of β -cyclodextrin were mixed in 500 ml tetrahydrofuran and stirred at 25° C for about 30 minutes. The solvent was evaporated at reduced

pressure. A white solid of the 5-pentyl-1,3-benzenediol/cyclodextrin complex, about 36 g, was obtained.

Example 2

Preparation of (-)-2-(p-mentha-2,8-diene-3-yl)pentylbenzene-1,3-diol:

The freshly prepared olivetol/cyclodextrin complex of Example 1 and 9 g of MgSO_4 were mixed together and stirred in 500 ml of tetrahydrofuran. The reaction mixture was cooled in an ice water bath to keep the temperature at about 5° C. 4.4 g of (+)-2,8-menthadiene-1-ol was placed in an addition funnel and p-TSA acid was placed into a syringe. The (+)-2,8-menthadiene-1-ol and the acid catalyst were added to the reaction mixture drop wise over 15 minutes. The reaction progress was monitored by HPLC and, upon completion of the reaction, an excess of NaHCO_3 was added to quench the reaction.

Salts were filtered out from the reaction mixture and the organic solvent was evaporated, leaving about 7.5 g of an oil. The oil was dissolved into 100 ml of petroleum ether and was washed with 300 ml of water twice and brine solution once. The product mixture was purified via chromatography on a silica gel column utilizing heptane/acetonitrile (98:2) as the mobile phase. A fraction contained the (-)-cannabidiol, also known as (-)-2-(p-mentha-2,8-diene-3-yl)pentylbenzene-1,3-diol, which was concentrated to give an oil.

^1H NMR δH (300 MHz, CHCl_3): 0.89(3H,d), 1.27 (4H, m), 1.56 (2H,m), 1.65(3H,s), 1.79 (3H,s), 2.11 (2H,m), 2.44(3H, m), 3.85(1H,d), 4.6 (2H,d), 5.58 (1H,s), 6.22 (2H,s). ^{13}C

NMR δ II (300mHz, CHCl₃): 14.6, 20.8, 23.3, 24.3, 28.7, 30.8, 37.4, 45.6, 108.2, 110.0, 111.4, 111.6, 124.2, 140.7, 143.5, 145.4, 156.3.

Example 3

Preparation of (-)-trans- Δ^9 -tetrahydrocannabinol:

The freshly prepared olivetol/cyclodextrin complex of Example 1 and 9 g of MgSO₄ were mixed together in 500 ml of tetrahydrofuran. The reaction mixture was cooled in an ice water bath to keep the temperature at about 5° C. 4.4 g of (+)-2,8-menthadiene-1-ol was placed in an addition funnel and BF₃Et₂O acid was placed into a syringe. The (+)-2,8-menthadiene-1-ol and the acid catalyst were added to the reaction mixture drop wise over 15 minutes. The reaction progress was monitored by HPLC and, upon completion of the reaction, an excess of NaHCO₃ was added to quench the reaction. Salts were filtered out from the reaction mixture and the organic solvent was evaporated to give an oil. Approximately 7.0 g of the oil was obtained as a mixture of (-)-trans- Δ^9 -tetrahydrocannabinol and some minor amount of (-)-trans- Δ^8 -tetrahydrocannabinol. The oil was dissolved into 100 ml of petroleum ether and was washed with 300 ml of water twice and brine solution once. The product mixture was purified via chromatography on a silica gel column and (-)-trans- Δ^9 -tetrahydrocannabinol eluted with heptane/acetonitrile (98:2) as mobile phase. A fraction containing the (-)-trans- Δ^9 -tetrahydrocannabinol, with purity over 98%, was concentrated to give a light yellow oil.

Having described the invention in detail, those skilled in the art will appreciate that modifications may be made of the invention without departing from its spirit and scope. Therefore, it is not intended that the scope of the invention be limited to the

specific embodiments described. Rather, it is intended that the appended claims and their equivalents determine the scope of the invention.

UNITED STATES PATENT AND TRADEMARK OFFICE
DOCUMENT CLASSIFICATION BARCODE SHEET




claims

5

Claims:

Claims:

1. A composition comprising an olivetol derivative complexed with at least one cyclodextrin.
2. The composition according to claim 1 wherein the at least one cyclodextrin includes a cyclodextrin selected from the group consisting of natural α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin or modified synthetic cyclodextrin, such as (2-hydroxy-propyl)- β -cyclodextrin, (2-carboxyethyl)- α , β , γ -cyclodextrin, (2,6-Di-O)-ethyl- β -cyclodextrin and (2-hydroxy-ethyl)- β -cyclodextrin.



wherein R_1 and R_2 are H or an alkyl or alcohol; and wherein R_3 is selected from the group consisting of normal alkyl groups having 1 to about 10 carbons, branched alkyl groups having 1 to about 10 carbons and aryl groups.

4. The composition according to claim 1 wherein the olivetol derivative is olivetol.
5. A composition comprising olivetol complexed with β -cyclodextrin.
6. A process for preparing a cannabinoid compound comprising:

complexing an olivetol derivative with at least one cyclodextrin; and reacting at least one terpenoid with the complexed olivetol to produce the cannabinoid compound.

7. The process according to claim 4 wherein the at least one cyclodextrin includes a cyclodextrin selected from the group consisting of natural α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin or modified synthetic cyclodextrin, such as (2-hydroxypropyl)- β -cyclodextrin, (2-carboxyethyl)- α , β , γ -cyclodextrin, (2,6-Di-O)-ethyl- β -cyclodextrin and (2-hydroxy-ethyl)- β -cyclodextrin.

8. The process according to claim 4 wherein the at least one terpenoid is selected from the group consisting of (-)-verbenol, (+)-chrysanthanol, (+)-p-mentha-2,8-diene-2-ol, (+)-trans-2-carene epoxide, (+)-3-carene oxide and (+)-p-mentha-2-ene-1,8-diol.

9. The process according to claim 4 further including maintaining a temperature below room temperature while reacting the at least one terpenoid with the complexed olivetol derivative.

10. The process according to claim 9 wherein the temperature is about 0° C to about 15° C.

11. The process according to claim 4 further including adding at least one acid catalyst.

12. The process according to claim 4 further including quenching the reaction of the at least one terpenoid with the complexed olivetol derivative with a base.

13. The process according to claim 4 wherein the cannabinoid is a naturally occurring component of cannabis.
14. The process according to claim 4 wherein the cannabinoid is a synthetic analog of cannabis.
15. A process for preparing a cannabidiol compound comprising:
complexing an olivetol derivative with at least one cyclodextrin; and
reacting at least one terpenoid with the complexed olivetol derivative at a temperature low enough to result in the production of a cannabidiol compound.
16. The process according to claim 15 wherein the at least one cyclodextrin includes a cyclodextrin selected from the group consisting of natural α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin or modified synthetic cyclodextrin, such as (2-hydroxy-propyl)- β -cyclodextrin, (2-carboxyethyl)- α , β , γ -cyclodextrin, (2,6-Di-O)-ethyl- β -cyclodextrin and (2-hydroxy-ethyl)- β -cyclodextrin.
17. The process according to claim 15 wherein the at least one terpenoid is selected from the group consisting of (-)-verbenol, (+)-chrysanthanol, (+)-p-mentha-2,8-diene-2-ol, (+)-trans-2-carene epoxide, (+)-3-carene oxide and (+)-p-mentha-2-ene-1,8-diol.
18. The process according to claim 15 further including adding at least one acid catalyst while reacting the at least one terpenoid with the complexed olivetol derivative, wherein the acid catalyst is selected to result in the formation of the cannabidiol.

19. The process according to claim 15 further including quenching the reaction of the at least one terpenoid with the complexed olivetol derivative with a base.
20. A process for preparing Δ^9 -tetrahydrocannabinol comprising:
complexing olivetol with at least one cyclodextrin; and
reacting the complexed olivetol with (+)-p-mentha-2,8-diene-1-ol to form Δ^9 -tetrahydrocannabinol.
21. The process according to claim 20 wherein the at least one cyclodextrin includes a cyclodextrin selected from the group consisting of natural α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin or modified synthetic cyclodextrin, such as (2-hydroxypropyl)- β -cyclodextrin, (2-carboxyethyl)- α , β , γ -cyclodextrin, (2,6-Di-O)-ethyl- β -cyclodextrin and (2-hydroxyethyl)- β -cyclodextrin.
22. The process according to claim 20 further including maintaining a temperature below room temperature while reacting the (+)-p-mentha-2,8-diene-1-ol with the complexed olivetol.
23. The process according to claim 20 wherein the temperature is about 0° C to about 15° C.
24. The process according to claim 20 further including adding at least one acid catalyst while reacting the (+)-p-mentha-2,8-diene-1-ol with the complexed olivetol.
25. The process according to claim 20 further including quenching with the reaction of the (+)-p-mentha-2,8-diene-1-ol with the complexed olivetol with a base.
26. A process for preparing Δ^9 -tetrahydrocannabinol comprising:
complexing olivetol with β -cyclodextrin; and

reacting the complexed olivetol with (+)-p-mentha-2,8-diene-1-ol to form Δ^9 -tetrahydrocannabinol.

27. The process according to claim 26 further including maintaining a temperature below room temperature while reacting the (+)-p-mentha-2,8-diene-1-ol with the complexed olivetol.

28. The process according to claim 27 wherein the temperature is about 0° C to about 15° C.

29. The process according to claim 26 further including adding at least one acid catalyst while reacting the (+)-p-mentha-2,8-diene-1-ol with the complexed olivetol.

30. The process according to claim 26 further including quenching the reaction of the (+)-p-mentha-2,8-diene-1-ol with the complexed olivetol with a base.

Abstract


An cyclodextrin-olivetol derivative complex is provided. The complex effectively blocks reaction at specific carbons to prevent unwanted reactions. A process for preparing a cannabinoid compound is further provided. The process comprises reacting at least one terpenoid with the cyclodextrin-olivetol derivative complex to produce the cannabinoid compound.

45 03 44 65 22 44 03 30 44 44 24 23 03 22

UNITED STATES PATENT AND TRADEMARK OFFICE
DOCUMENT CLASSIFICATION BARCODE SHEET



Abstract



Level - 2
Version 1.1
Updated - 8/01/01